Category Archives: Evergreening

Report on Pharmaceutical Patents in India – How our safeguards against evergreening have failed, and why the system must be reformed

  The recent report on “Pharmaceutical Patent Grants in India How our safeguards against evergreening have failed, and why the system must be reformed” shows immense irregularities in grant of patents in the country. Over the past decades India’s patent system has … Continue reading

Posted in Evergreening, Fix the patent law, India, Indian Patent Law, Indian Patent Office | Leave a comment

Gilead’s Patents on Hepatitis C Drug Challenged by Consumer Group

Source: Bloomberg Gilead Sciences Inc.’s U.S. patents on the blockbuster $84,000 hepatitis C treatment Sovaldi were challenged by a consumer group that’s battled the drugmaker around the world over the pricing.  The Initiative for Medicines, Access & Knowledge, a nonprofit focused on … Continue reading

Posted in Cancer, Evergreening, Hepatitis C, Patent, Uncategorized | Leave a comment

India grants Pfizer patent for pneumonia vaccine

Source: Live Mint India has granted Pfizer a patent for Prevnar 13 pneumonia vaccine, in spite of opposition from the heath group Médecins Sans Frontières (MSF) New Delhi: India has granted US pharmaceutical company Pfizer Inc. a patent for its pneumonia … Continue reading

Posted in Evergreening, Indian Patent Law, Patent, Patent Opposition, Uncategorized, Vaccines | Leave a comment

Indian patent for Pfizer’s pneumonia vaccine seen as a blow to aid group

Source: The HinduBusinessLine MUMBAI, AUGUST 22:   The grant of an Indian patent to Pfizer’s Prevenar13, a pneumococcal conjugate vaccine, has raised the hackles of pro-health group MSF who are worried that it will hamper access to the vaccine. “It’s unfair … Continue reading

Posted in Evergreening, Indian Patent Law, Patent, Patent Opposition, Uncategorized, Vaccines | Leave a comment

Draft Pharmaceutical Policy, 2017

Source: All India Drug Action Network (AIDAN) The Department of Pharmaceuticals has circulated a Draft Pharmaceutical Policy, 2017 which can be accessed here. The draft policy identifies the following key objectives: a. Making essential drugs accessible at affordable prices to the … Continue reading

Posted in API, Biologics/Biosimilars, Evergreening, Innovation, IPR, Patent, R&D, Uncategorized | Leave a comment

The Trump Executive Order on drug prices: not what was promised nor needed, and contrary to US self interest

Source: Medium Emily Kopp has a big scoop for Kaiser Health News. She has obtained a six page document outlining the draft provisions or objectives of a proposed Presidential Executive Order (EO) on drug prices. She has shared some of … Continue reading

Posted in Compulsory Licensing, Data Exclusivity, Evergreening, IPR Enforcement, Special 301 report, Uncategorized, UNHLP report, US Pressure | Leave a comment

June 2017 Alert: Pressure on countries hiked by US on IP

The US government is stepping up on TRIPS plus pressure through bilateral forums based on a US law that passed under Obama to strengthen IPR enforcement and the 301 process. Countries targeted include India, Indonesia, China, Thailand, Ukraine in Asia … Continue reading

Posted in Compulsory Licensing, Data Exclusivity, Evergreening, IPR Enforcement, Special 301 report, Uncategorized, UNHLP report, US Pressure | Leave a comment